How advanced modeling reduces uncertainty and strengthens market access strategy

Regulatory approval is no longer enough to ensure commercial success. Today, therapies must also demonstrate value to payers and health technology assessment (HTA) bodies, often requiring evidence that goes beyond traditional clinical endpoints.

In this guide, you’ll learn how to bridge the gap between regulatory and payer expectations using advanced modeling approaches, including Quantitative Systems Pharmacology (QSP) and Model-Based Meta-Analysis (MBMA), within a Model-Informed Drug Development (MIDD) framework.

By integrating these methods earlier in development, teams can generate decision-grade evidence that supports both regulatory approval and reimbursement success.

What you’ll learn

• How to address the “fourth hurdle” of reimbursement earlier in development
• How QSP and MBMA inform target selection, trial design, and differentiation
• How to quantify comparative effectiveness before head-to-head trials
• How to design Phase 3 programs aligned with payer expectations
• How to strengthen your economic and clinical value narrative

Why download this guide

Late-stage evidence gaps can delay access, limit pricing flexibility, and reduce return on investment. This guide provides a practical framework to align development strategy with payer requirements, helping you reduce uncertainty, optimize decisions, and improve the likelihood of reimbursement success.